BR9508053A - Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga - Google Patents

Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga

Info

Publication number
BR9508053A
BR9508053A BR9508053A BR9508053A BR9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A BR 9508053 A BR9508053 A BR 9508053A
Authority
BR
Brazil
Prior art keywords
construction
production
heterologous protein
yeast strain
vector dna
Prior art date
Application number
BR9508053A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas Borglum Kjeldsen
Knud Vad
Jokob Brandt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9508053A publication Critical patent/BR9508053A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9508053A 1994-06-17 1995-06-16 Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga BR9508053A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK71294 1994-06-17
PCT/DK1995/000250 WO1995035384A1 (fr) 1994-06-17 1995-06-16 Proteines comportant une extension a l'extremite n-terminale, exprimees par une levure

Publications (1)

Publication Number Publication Date
BR9508053A true BR9508053A (pt) 1997-08-12

Family

ID=8096676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508053A BR9508053A (pt) 1994-06-17 1995-06-16 Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga

Country Status (16)

Country Link
EP (1) EP0765395A1 (fr)
JP (1) JP3730255B2 (fr)
CN (1) CN1131312C (fr)
AU (1) AU2733595A (fr)
BR (1) BR9508053A (fr)
CA (1) CA2192943A1 (fr)
CZ (1) CZ363796A3 (fr)
FI (1) FI965030A (fr)
HU (1) HUT75840A (fr)
IL (1) IL114160A (fr)
MX (1) MX9606536A (fr)
NO (1) NO965411L (fr)
PL (1) PL317761A1 (fr)
SG (1) SG47883A1 (fr)
WO (1) WO1995035384A1 (fr)
ZA (1) ZA954983B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
JP4341859B2 (ja) 1996-12-13 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス， インコーポレーテッド 酵母での異種タンパク質の発現の方法
AU7873798A (en) * 1996-12-20 1998-07-17 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
EP1049790A1 (fr) 1998-01-23 2000-11-08 Novo Nordisk A/S Procede servant a preparer des polypeptides souhaites dans de la levure
RU2002120513A (ru) 1999-12-29 2004-03-27 Ново Нордиск А/С (DK) Способ производства предшественников инсулина и аналогов предшественников инсулина с повышенным выходом ферментации у дрожжей
WO2003010185A2 (fr) * 2001-07-24 2003-02-06 Novo Nordisk A/S Procede pour produire des polypeptides acyles
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
WO2004085472A1 (fr) * 2003-03-27 2004-10-07 Novo Nordisk A/S Procede de fabrication de precurseurs de l'insuline humaine et insuline humaine
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
EP1917363B1 (fr) 2005-08-16 2011-06-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
ES2542146T3 (es) * 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
WO2008034881A1 (fr) 2006-09-22 2008-03-27 Novo Nordisk A/S Analogues de l'insuline résistants à une protéase
EP2069502B1 (fr) 2006-09-27 2014-02-26 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
ES2425413T3 (es) 2006-11-22 2013-10-15 Novo Nordisk A/S Método para preparar carboxipeptidasa activada
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
EP2178909B1 (fr) 2007-08-13 2015-10-21 Novo Nordisk A/S Analogues de l'insuline à action rapide
EP2178912B1 (fr) 2007-08-15 2015-07-08 Novo Nordisk A/S Analogues de l'insuline comprenant un fragment acyle et alkylène glycol
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
EP2262539B1 (fr) 2008-04-01 2015-07-15 Novo Nordisk A/S Conjugués insuline-albumine
ES2440289T3 (es) 2009-06-26 2014-01-28 Novo Nordisk A/S Preparación que comprende insulina, nicotinamida y arginina
US8815541B2 (en) 2009-11-25 2014-08-26 Novo Nordisk A/S Method for making polypeptides
EP2585483A1 (fr) 2010-06-23 2013-05-01 Novo Nordisk A/S Insuline humaine contenant des liaisons disulfures supplémentaires
US8853155B2 (en) 2010-06-23 2014-10-07 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
EP2585484A1 (fr) 2010-06-23 2013-05-01 Novo Nordisk A/S Analogues de l'insuline contenant des liaisons disulfures supplémentaires
CN103249427A (zh) 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
RU2013130374A (ru) 2010-12-14 2015-01-20 Ново Нордиск А/С Препарат, содержащий инсулин, никотинамид и аминокислоту
US9260503B2 (en) 2011-06-15 2016-02-16 Novo Nordisk A/S Multi-substituted insulins
WO2013186138A1 (fr) 2012-06-14 2013-12-19 Novo Nordisk A/S Préparation comprenant de l'insuline, du nicotinamide et de l'arginine
CA2890048C (fr) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. Insuline et analogues d'insuline a base de peptide a partie terminale carboxy (ptc) o-glycosylee
EP3004156A1 (fr) 2013-06-07 2016-04-13 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
US20160376330A1 (en) 2014-02-28 2016-12-29 Novo Nordisk A/S Mating factor alpha pro-peptide variants
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
EP3341403B1 (fr) 2015-08-25 2022-01-05 Novo Nordisk A/S Nouveaux dérivés d'insuline et utilisations médicales de ceux-ci
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
WO2017202936A1 (fr) * 2016-05-24 2017-11-30 Novo Nordisk A/S Composés mic-1 et leur utilisation
BR112020002364A2 (pt) 2017-08-17 2020-09-01 Novo Nordisk A/S derivado de insulina, produto intermediário, uso de um derivado de insulina, e, métodos para o tratamento ou prevenção de diabetes, diabetes do tipo 1, diabetes do tipo 2, tolerância à glicose comprometida, hiperglicemia, dislipidemia, obesidade, síndrome metabólica, hipertensão, distúrbios cognitivos, aterosclerose, infarto do miocárdio, acidente vascular cerebral, distúrbios cardiovasculares, doença cardíaca coronariana, síndrome intestinal inflamatória, dispepsia, hipotensão ou úlceras gástricas, e para determinar a seletividade de um composto de insulina
EP3807306A4 (fr) * 2018-06-18 2022-04-06 Unichem Laboratories Limited Séquence leader pour une expression plus élevée de protéines recombinées
RS65822B1 (sr) 2019-12-11 2024-09-30 Novo Nordisk As Novi insulinski analozi i njihova upotreba
WO2023144240A1 (fr) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Dérivés d'insuline sensibles au glucose et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593518B1 (fr) * 1985-05-02 1989-09-08 Transgene Sa Vecteurs d'expression et de secretion de l'hirudine par les levures transformees
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
CA1340772C (fr) * 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
WO1992013951A1 (fr) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production de serumalbumine humaine dans des cellules de levure methylotrophique

Also Published As

Publication number Publication date
JP3730255B2 (ja) 2005-12-21
IL114160A (en) 2006-12-31
HU9603476D0 (en) 1997-02-28
HUT75840A (en) 1997-05-28
ZA954983B (en) 1996-02-14
IL114160A0 (en) 1995-10-31
FI965030A0 (fi) 1996-12-16
NO965411D0 (no) 1996-12-16
SG47883A1 (en) 1998-04-17
CZ363796A3 (en) 1997-05-14
AU2733595A (en) 1996-01-15
CN1131312C (zh) 2003-12-17
CN1152942A (zh) 1997-06-25
EP0765395A1 (fr) 1997-04-02
CA2192943A1 (fr) 1995-12-28
JPH10501695A (ja) 1998-02-17
WO1995035384A1 (fr) 1995-12-28
MX9606536A (es) 1997-03-29
FI965030A (fi) 1997-02-14
NO965411L (no) 1997-02-14
PL317761A1 (en) 1997-04-28

Similar Documents

Publication Publication Date Title
BR9508053A (pt) Construção de DNA vetor de expressão recombinante cepa de levedura e processo para a produção de uma proteina heteróloga
BR8202422A (pt) Vetor de clonacao de bacillus processo para sua construcao molecula de dna recombinante processo para sua construcao e processo para a producao de um polipeptidio
FI973055A (fi) Soluja yhdistelmä-DNA-adenovirusten tuottamiseksi
BRPI9801092B1 (pt) processo para a produÇço de fator recombinante viii e meio de cultura de cÉlula.
DE69611102D1 (de) Verstärkung der mutagenese von nukleinsäuren
BR9403442A (pt) Silanos, processo para sua produção e aplicação dos ditos silanos
BR8101972A (pt) Vetor, processo para sua producao, processo para produzir uma molecula recombinante de dna, e processo para produzir um polipeptideo
BR9606453A (pt) Microválvula e processo para a fabricação de uma microválvula
EE03590B1 (et) Peptiidide ja proteiinide aerosoolvormid
BR9607669A (pt) Derivado de hormõnio de peptídeo e processo de proporcionar o mesmo
NO971875D0 (no) Cathepsin 02 protease
BR9709733A (pt) Construção de dna quimérico recominante e processo para seleção de linhagens
BR9101137A (pt) Metodo para a preparacao de um vetor hibrido,processo para a preparacao de uma molecula de dna,metodo para a preparacao de um hospedeiro e para a preparacao de um polipeptidio e metodo para a preparacao de psm puro
EE200000152A (et) Aminoterminaalselt kärbitud MCP-2 vormid, DNA molekulid, ekspressioonivektor, peremeesrakk, rekombinantne meetod proteiini valmistamiseks, proteiini kasutamine ning farmatseutiline kompositsioon
BR9508714A (pt) Composto processo de preparação de estreptogramas por muta-síntese sequencia nucleotídica dna recombinante vetor utilização de uma sequencia e/ou de um vetor polipetídeo cepa mutante e composição farmacèutica
BRPI9600729B8 (pt) vetor de expressão, microorganismo transgênico, processo de clonagem de um ácido nucléico e processo para preparação de uma proteína e cepa de levedura transformada
GB9724879D0 (en) Process for the production of protein and products thereof
BR9606270A (pt) Processo para a produção da proteína do interferon beta-cis humano recombinante e proteína de interferon beta-cis humano recombinante
AU3131195A (en) Vectors and transformed host cells for recombinant protein production at reduced temperatures
BR9709721A (pt) Polinucleotídeo purificado e isolado dna vetor célula hospedeira processo para prodzir quitanase humama para tratar uma infecção fúngica e para reduzir a quantidade de um ant-fúngico não-quitanase fragmento de polipeptídeo de quitanase humama linha de células de hiridoma anticorpo monoclonal e composição farmacéutica
EP1028095A4 (fr) Materiau de renforcement, procede de production associe, procede de renforcement/reparation a l'aide de ce materiau, structure de renforcement/reparation, et element structurel
DE59712554D1 (de) Rekombinante expression von s-layer-proteinen
BR9306150A (pt) Endo--1,4-glucanase sequéncia de dna recombinante vetor hospedeiro transformado contendo o vetor processo para a produç o de endo- -1,4-glucanase preparaç o de enzima e uso de endo- -1,4-glucanase
EP0754757A3 (fr) Promoteur végétal et son utilisation
FI953422A0 (fi) Autolysoivia fuusioproteiineja hyväksikäyttävät ilmentämisjärjestelmät ja uusi pelkistävä polypeptidi

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law